Publication | Closed Access

A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies

Young AdultsOncologyRefractory Solid MalignanciesPharmacotherapyAnti-cancer AgentCancer TreatmentMedicineRadiation OncologyCancer Research